Coagulation factor II and Coagulation factor X (FIIa and FXa)

Thrombin (activated Factor II) and Factor Xa are essential serine proteases in the blood coagulation cascade, serving as critical regulators of hemostasis (StatPearls, 2023). Factor Xa is the primary component of the prothrombinase complex, which catalyzes the conversion of prothrombin into active thrombin (UniProt P00742). Thrombin then performs the final step of clot formation by converting fibrinogen into fibrin and activating platelets (UniProt P00734). These proteins are major therapeutic targets for anticoagulants used to treat and prevent thromboembolic conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism (PubMed, PMC6062446). Pharmacological intervention includes direct inhibitors like rivaroxaban (targeting FXa) and dabigatran (targeting Thrombin), as well as indirect inhibitors like heparin that target both enzymes via antithrombin (NIH, 2022). Inhibition of these factors effectively reduces the generation of fibrin, thereby preventing the expansion of existing thrombi and the formation of new ones. Monitoring of therapy is often required using assays such as the International Normalized Ratio (INR) or anti-Xa levels to balance efficacy and bleeding risk.

Other names

ThrombinFactor XaProthrombinStuart-Prower factorF2F10ThrombokinaseCoagulation factor IIaCoagulation factor Xa

Drugs targeting these enzymes act by either directly binding to the active site (direct inhibitors) or by inducing a conformational change in antithrombin to accelerate the natural neutralization of these proteases (indirect inhibitors), thereby halting the production of fibrin and preventing thrombus formation (StatPearls, 2023).